pcn poster

Posters

The Impact of Second-Generation Antipsychotic Medication Side-Effects on Functioning From a Schizophrenia Patient Perspective: a Cross-Sectional, Observational, Patient Centered, Web Survey Study

Background: Second-generation antipsychotics (SGAs) are associated with well-known side effects (SEs). We aimed to gain a patients’ perspective on how specific SEs impact daily functionin...

William Lenderking , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Huda Shalhoub , PhD;

Ann Hartry , PhD;

Mallik Greene , PhD, DBA;

Laetitia Bouerat Duvold , PhD;

Owen Cooper , MSc;

Leah Kleinman , DrPH;

Randall Bender , PhD;

Rajiv Tandon , MD;

03/01/2019

The Relationship Between Patient Activation and Healthcare Service Utilization and Cost Among Mental Health Patients: Interim Analysis of Integrated Claims and Survey Data.

Background Schizophrenia (Sz), bipolar disorder (BD), and major depressive disorder (MDD) are associated with elevated burden and cost of care. Compared to medical patients, far less is k...

03/01/2019

The Role of Long-Acting Injectable Antipsychotics in Preventing Relapse in Early Psychosis Patients With Concurrent Cannabis Use Disorder

Cannabis use, which is commonly observed in patients with early psychosis, is associated with increased risk of relapse and rehospitalization. Adverse outcomes associated with cannabis us...

03/01/2019

Trauma Focused Screening and CBT With Adolescents Living With HIV in Swaziland: A Student Perspective

The purpose of this exploratory study was to improve screening for depression and stigma among youth living with HIV in Swaziland, to introduce evidence-based psychotherapy and train loc...

03/01/2019

Treatment Discontinuation of Long-Acting Injectables or Oral Atypical Antipsychotics Among Medicaid Recipients With Schizophrenia

OBJECTIVE: Compare treatment discontinuation of atypical long-acting injectables (LAIs) and oral atypical antipsychotics (OAA) in patients with schizophrenia.

Xue Song , PhD;

Antoine C. El Khoury , PhD;

Matthew Brouillette , MPH;

Kruti Joshi , MPH, MD;

David Smith , PhD, MD, MBBS, DPM;

03/01/2019

Treatment Effect of Once-Monthly Paliperidone Palmitate Compared With Oral Antipsychotics in African American Patients Diagnosed With Schizophrenia With a History of Criminal Justice System Involvement

Objective: The purpose of this subgroup analysis was to examine the efficacy in delaying time to relapse of paliperidone palmitate once-monthly (PP1M) compared with oral antipsychotics (O...

03/01/2019

Update on a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating SPN-810 for the Treatment of Impulsive Aggression (IA) in Pediatric Patients with ADHD

Background: Aggression is one of the most common reasons for psychiatric referral in children. The most prevalent subtype of maladaptive aggression is IA – which is reactive, overt, and o...

Azmi Nasser , PhD;

Fatima Chowdhry , MD;

Toyin Adewole , MD, MPH;

Tesfaye Liranso , PhD;

Jiahong Xu , MS, MPH;

Ronald Marcus , MD;

03/01/2019

Using a Genetic Test (Combinatorial Pharmacogenomics)To Help Choose Patient-Specific Antidepressants for Depression: a Large, Blinded, Randomized Control Trial

Background: Here we present the first prospective, large-scale, patient- and rater-blind, randomized controlled trial evaluating the utility of combinatorial pharmacogenomic (PGx) testing...

Anthony Rothschild , MD;

Boadie Dunlop , MD;

Michael Thase , MD;

Charles Conway , MD;

Richard Shelton , MD;

Brent Forester , MD, MSc;

James Li , MS, PhD;

Francis Mondimore , MD;

Krystal Brown , PhD;

Matthew Macaluso , DO;

Michael Jablonski , PhD;

Alexa Gilbert , MSc, MBA;

Bryan Dechairo , PhD;

Lindsey Burns , MBA;

Charles DeBattista , MD;

Sagar Parikh , MD;

John Greden , MD;

03/01/2019

Using Administrative Data to Identify Predictors of Antipsychotic Medication Polypharmacy

Background: Antipsychotic medications are reliable treatments for behavioral health (BH) conditions, especially when patients fail to respond to other treatments. Little is known about an...

03/01/2019

Validation of Goal Attainment Scaling for Depression: Initial Findings From an Open-label Study in Patients Switching to Vortioxetine

Goal attainment scaling (GAS) for evaluating individualized patient treatment goals and progress was adapted for MDD (GAS-D) in an open-label study in patients switching to vortioxetine (...

Maggie McCue , MS, RD;

Lambros Chrones , MD;

Anna Eramo , MD;

Mark Opler , PhD, MPH;

Andrea Norcini Pala , PhD;

Sagar Parikh , MD;

David Hellerstein , MD;

03/01/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products